Paediatric patients with early-onset atopic dermatitis show higher uveitis risk

News
Article

The study findings support the need to consider ophthalmologic monitoring in children with early-onset atopic dermatitis

A dermatologist examines a child's arm for evidence of atopic dermatitits. Concept image for link between AD and paediatric uveitis. Image credit: ©Kate – stock.adobe.com

Image credit: ©Kate – stock.adobe.com

Taiwanese investigators found in their cohort study that children with early-onset atopic dermatitis had an increased risk of developing uveitis and should be carefully observed to identify that onset.1 The study was led by Yung-Yu Chu, MD, from the Department of Ophthalmology, Chi Mei Medical Center, Tainan, Taiwan.

The researchers retrospectively evaluated the electronic health records of US patients in TriNetX, a collaborative research network, to identify patients with early-onset atopic dermatitis. The study also included matched controls without atopic dermatitis and excluded patients with uveitis before atopic dermatitis was diagnosed. The primary outcome was the hazard ratio (HR) for developing paediatric uveitis in the atopic dermatitis cohort compared with the matched controls, the authors explained.

The search of the health records identified 114,889 patients in the atopic dermatitis and control cohorts; the respective mean patient ages were 0.5 year and 0.6 years.

The results showed that 94 patients with atopic dermatitis developed paediatric uveitis compared with 58 controls (HR, 1.92 [95% confidence interval [CI], 1.38-2.66]).

The results also found that patients in the atopic dermatitis cohort who were not treated with dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals), which is approved to treat the disease (89 of 113, 284 [0.08%] vs 59 of 113, 284 [0.05%]; HR, 1.77 [95% CI, 1.27-2.46]) and patients without autoimmune conditions (80 of 114, 425 [0.07%] vs 61 of 114,425 [0.05%]; HR, 1.52 [95% CI, 1.09-2.12]) also had an increased risk of developing uveitis.

The severity of atopic dermatitis also was an important factor, in that those with severe disease had a higher risk of developing paediatric uveitis compared with those with nonsevereatopic dermatitis (12 of 3,004 [0.40%] vs 97 of 126,482 [0.08%]; HR, 3.64 [95% CI, 2.00-6.66]), Dr Chu and colleagues reported.

Investigators concluded, “This cohort study of children with early-onset AD found an elevated risk of paediatric uveitis compared with matched controls, independent of autoimmune conditions or dupilumab use. These findings support the potential need to consider ophthalmologic monitoring in children with early-onset AD to try to detect and subsequently manage uveitis if it develops.”

They also advised that the relationship between atopic dermatitis and paediatric uveitis may be underexplored and, therefore, warrants large-scale, multicentre studies.

Reference
  1. Chu Y-Y, Sung C-H, Lin Y-S, et al. Risk of developing pediatric uveitis among patients with early-onset atopic dermatitis.JAMA Ophthalmol.Published online April 3, 2025. doi:10.1001/jamaophthalmol.2025.0366

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.